Pulnovo Medical, a medical devices company focusing on pulmonary hypertension (PH) and heart failure (HF), announced the closing of nearly $100 million in Series C financing.
The funding round was co-led by Qiming Venture Partners and existing shareholder Lilly Asia Ventures, with existing investors OrbiMed and Gaorong Capital participating on a super pro-rata basis.
Pulnovo Medical said the funding proceeds would be used to advance its global clinical trials, international business expansion, and strategic initiatives.
Founded in 2013, Pulnovo Medical is focused on developing superior therapeutic solutions for various stages of HF to enhance patient outcomes.
Cynthia Chen, Chairlady, Executive Chairwoman, and President of Pulnovo Medical, said that the proceeds of this round will support two upcoming FDA trials for Group I PH and Group II PH (chronic heart failure combined with PH) planned this year.